Extended case-control study results on thromboembolic outcomes among transdermal contraceptive users

被引：57

作者：

Dore, David D. ^{[1
,2
]}

Norman, Heather ^{[1
]}

Loughlin, Jeanne ^{[1
]}

Seeger, John D. ^{[1
,3
]}

机构：

[1] I3 Drug Safety, Waltham, MA 02451 USA

[2] Brown Univ, Dept Community Hlth, Warren Alpert Med Sch, Providence, RI 02912 USA

[3] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA

来源：

CONTRACEPTION | 2010年 / 81卷 / 05期

关键词：

Transdermal contraceptive; Venous thromboembolism; Case-control study; Pharmacoepidemiology; NONFATAL VENOUS THROMBOEMBOLISM; MYOCARDIAL-INFARCTION; ORAL-CONTRACEPTIVES; ETHINYL ESTRADIOL; SYSTEM USERS; PATCH; STROKE; NORGESTIMATE; RISK;

D O I：

10.1016/j.contraception.2009.12.009

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Background: We extended an earlier study that found a twofold higher risk of venous thromboembolism (VTE) associated with the transdermal contraceptive system relative to norgestimate-containing oral contraceptives (NGM-OC). Study Design: This case-control study identified potential cases of VTE, acute myocardial infarction (AMI) and stroke from 24 months of additional health care claims, with adjudication via medical records. Randomly selected controls were matched to cases on age (15-44 years) and characteristics of contraception use. Conditional logistic regression models provided odds ratios (ORs) and 95% confidence intervals (CIs). Results: The transdermal contraceptive system was associated with a twofold higher risk of VTE (OR 2.0; 95% Cl 1.2-3.3) compared with users of NGM-OC. The OR for stroke was 0.6 (95% Cl 0.1-3.2) and for AMI 1.2 (95% CI 0.3-4.7). Conclusion: This extension was consistent with the earlier study, showing a twofold increased risk of VTE associated with use of the transdermal contraceptive system relative to NGM-OC. (C) 2010 Elsevier Inc. All rights reserved.

引用

页码：408 / 413

页数：6

共 12 条

[1]

Cole JA, 2008, OBSTET GYNECOL, V111, P1449

[2] Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users [J].

Cole, J. Alexander ;

Norman, Heather ;

Doherty, Michael ;

Walker, Alexander M. .

OBSTETRICS AND GYNECOLOGY, 2007, 109 (02) :339-346

[3] Studying prescription drug use and outcomes with medicaid claims data - Strengths, limitations, and strategies [J].

Crystal, Stephen ;

Akincigil, Ayse ;

Bilder, Scott ;

Walkup, James T. .

MEDICAL CARE, 2007, 45 (10) :S58-S65

[4] Eligibility Criteria in Venous Thromboembolism, Myocardial Infarction, and Stroke Among Transdermal Contraceptive System Users [J].

Dore, David D. ;

Norman, Heather ;

Seeger, John D. .

OBSTETRICS AND GYNECOLOGY, 2009, 114 (01) :175-175

[5] Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 μg of ethinyl estradiol [J].

Jick, SS ;

Kaye, JA ;

Russmann, S ;

Jick, H .

CONTRACEPTION, 2006, 73 (03) :223-228

[6] Further results on the risk of nonfatal venous thromboembolism in users of the contraceptive transdermal patch compared to users of oral contraceptives containing norgestimate and 35 μg of ethinyl estradiol [J].

Jick, Susan ;

Kaye, James A. ;

Li, Lin ;

Jick, Hershel .

CONTRACEPTION, 2007, 76 (01) :4-7

[7] The contraceptive patch in relation to ischemic stroke and acute myocardial infarction [J].

Jick, Susan S. ;

Jick, Hershel .

PHARMACOTHERAPY, 2007, 27 (02) :218-220

[8] How far from non-differential does exposure or disease misclassification have to be to bias measures of association away from the null? [J].

Jurek, Anne M. ;

Greenland, Sander ;

Maldonado, George .

INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2008, 37 (02) :382-385

[9]

National Center for Health Statistics, NAT DEATH IND

[10]

Phelps JY, 2009, OBSTET GYNECOL, V113, P712, DOI 10.1097/AOG.0b013e3181a891f4

← 1 2 →